文献速递浆细胞疾病

单中心45年真实世界多发性骨髓瘤患者生存改善趋势

Real-world data on survival improvement in patients with multiple myeloma treated at a single institution over a 45-year period.
PubMed 文献 · Br J Haematol · 2021-10-07

5年相对生存率从1970-1984年的27%升至后续两个时期的38%和56%,年轻患者改善更明显,但老年及体能状态差、疾病更晚期患者也有改善。

要点

  • 5年相对生存率从27%升至38%再至56%,跨越三个治疗年代。
  • 生存改善在年轻患者中更显著,但老年及一般状况差者亦获益。
  • 骨髓瘤仍不可治愈,真实世界数据证实新药时代生存持续改善。

核心结论

  • 45年间多发性骨髓瘤患者相对生存率显著提高,5年相对生存率从27%升至56%。
  • 生存改善在年轻患者中更明显,但在老年、体能状态差及疾病更晚期患者中亦观察到改善。

研究设计与样本

  • 按治疗年代分为三个日历期:1970-1984年(联合化疗)、1985-1999年(自体干细胞移植)、2000-2015年(新药)。
  • 采用相对生存率分析,排除一般人群预期死亡率后评估骨髓瘤相关死亡。

主要发现

  • 5年相对生存率从1970-1984年的27%升至1985-1999年的38%,再升至2000-2015年的56%。
  • 生存改善在年轻人群中更显著,但老年患者、体能状态差及疾病更晚期患者中亦有改善。

临床怎么用

  • 真实世界数据证实新药及移植等治疗策略的生存获益随时间推移持续扩大。
  • 老年及体能状态差、晚期患者同样可从现代治疗中获益,不应仅因年龄或一般状况排除治疗。

局限性

  • 单中心真实世界研究,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The prognostic landscape of multiple myeloma (MM) has evolved significantly over the last few decades. There are, however, few data measuring such improvement in real-world patients. This study aimed to investigate trends in survival improvement over 45 years, and the associated clinical factors, in an unselected population of patients with MM. Between 1970 and 2015, 1 161 MM patients were included. Patients were classified into three calendar periods (1970-1984, 1985-1999, and 2000-2015), according to the treatment received; polychemotherapy, autologous stem cell transplantation, and novel drugs respectively. We analysed relative survival (RS) to accurately evaluate MM-related death rates after excluding the mortality expected in the general population. RS at five years increased from 27% in 1970-1984 to 38% and 56% in the next two calendar periods respectively. The improvement to survival was greater in the younger population, but it was also observed in elderly patients and those with poor performance status and more advanced disease. Although myeloma is still a non-curable disease, encouraging results have been observed in the last decades. Progress is expected to continue with the use of new generations of anti-myeloma drugs, and will, hopefully, be documented in real-world patients by the appropriate population-based studies.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Rodríguez-Lobato LG, Pereira A, Fernández de Larrea C, et al. Real-world data on survival improvement in patients with multiple myeloma treated at a single institution over a 45-year period. Br J Haematol. 2021. PMID: 34622447. doi:10.1111/bjh.17888

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。